You have matched to 5 trials

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

A <span class="highlight">Basket</span> Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of using a tumor's genetic profile to select an FDA-approved targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with no standard treatment options. You must have results from a genomic or immunohistochemistry test approved by TAPUR. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive an FDA-approved targeted therapy based on your tumor's genetic profile.</p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The targeted therapy you receive will be selected based on your tumor's genetic profile.</li> <li class="seamTextUnorderedListItem">Your treatment may include one or more of the following: Abemaciclib, Futibatinib, Nivolumab, Ipilimumab, Olaparib, Palbociclib, Pembrolizumab, Regorafenib, Sunitinib, Talazoparib, Temsirolimus, Trastuzumab, Pertuzumab, Vemurafenib, Cobimetinib</li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> trials enroll people based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: ALK, ATM, BRAF, BRAF V600E/D/K/R, BRCA1/2, CDK4, CDK6, CDKN2A, CSF1R, FGFR1/2/3/4, HER2 (ERBB2), high mutational load and others, KIT, MET, MSI-H, mTOR, NRG1, PALB2, PDGFR, POLD1, POLE, RAF-1, RET, ROS1, TSC, VEGFR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT02693535' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.tapur.org/' target='_blank'>ASCO: TAPUR Study Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.net/research-and-advocacy/clinical-trials/what-tapur-study' target='_blank'>Cancer.Net (Video): What is the TAPUR Study?</a> </li><li class='seamTextUnorderedListItem'><a href='https://old-prod.asco.org/research-data/tapur-study/study-participation' target='_blank'>ASCO: TAPUR Study Participation</a> </li><li class='seamTextUnorderedListItem'><a href='http://www.onclive.com/conference-coverage/asco-2016/dr-edward-kim-on-ascos-tapur-trial' target='_blank'>OncLive (Video): About TAPUR</a> </li></ul>
1

Choosing Targeted Therapy Based on a Tumor's Genetic Makeup for Advanced Breast Cancer (TAPUR)

A <span class="highlight">Basket</span> Study: Targeted Agent and Profiling Utilization Registry (TAPUR) Study
Icon

Nearest Location:
3 miles
Kaiser Permanente - San Francisco Medical Center
San Francisco, CA

Icon

Visits:
Coincides with targeted therapy

Icon

ClinicalTrials.gov: NCT02693535

Icon

Phase II

2

Bemarituzumab Targeted Therapy for Advanced Triple Negative Breast Cancer that Expresses FGFR2b

A Phase 1b/2, Multicenter, Open-label <span class="highlight">Basket</span> Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of bemarituzumab, an experimental FGFR2b inhibitor.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that expresses FGFR2b who have received at least 1 line of therapy for advanced or metastatic disease. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bemarituzumab (AMG 552), by IV</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Please contact research site</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Bemarituzumab (AMG 552) is an experimental targeted therapy called a FGFR2b inhibitor. Targeting FGFR2b may slow or stop cancer cell growth.</li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. It is enrolling people with other types of cancer based on the kind of mutations found in their tumors.</li> <li class="seamTextUnorderedListItem">Targets or mutations: FGFR2b, FGFR</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT05325866' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.amgenpipeline.com/' target='_blank'>Amgen Drug Information Page: Bemarituzumab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/targeted-therapy' target='_blank'>Breastcancer.org: Targeted Therapy</a> </li></ul>
2

Bemarituzumab Targeted Therapy for Advanced Triple Negative Breast Cancer that Expresses FGFR2b

A Phase 1b/2, Multicenter, Open-label <span class="highlight">Basket</span> Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)
Icon

Nearest Location:
353 miles
City of Hope National Medical Center
Duarte, CA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT05325866

Icon

Phase I-II

3

BAY2927088 Targeted Therapy for Advanced Breast Cancer with HER2 Mutations

A Phase 2 Open-label <span class="highlight">Basket</span> Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of BAY2927088, an experimental targeted therapy.

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) breast cancer with a HER2 mutation who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">BAY2927088, by mouth, daily</li> <li class="seamTextUnorderedListItem">Questionnaires</li> <li class="seamTextUnorderedListItem">Heart tests</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Some breast cancers have changes or mutations to a gene called human epidermal growth receptor 2 (HER2). These mutations can help the cancer grow.</li> <li class="seamTextUnorderedListItem">BAY2927088 is an experimental anti-HER2 targeted therapy called a tyrosine kinase inhibitor. It may block abnormal HER2 which may slow or stop the growth of cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06760819' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://my.clevelandclinic.org/health/treatments/24984-tyrosine-kinase-inhibitors' target='_blank'>Cleveland Clinic: Tyrosine Kinase Inhibitors</a> </li></ul>
3

BAY2927088 Targeted Therapy for Advanced Breast Cancer with HER2 Mutations

A Phase 2 Open-label <span class="highlight">Basket</span> Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)
Icon

Nearest Location:
1643 miles
University of Texas MD Anderson Cancer Center
Houston, TX

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT06760819

Icon

Phase II

4

Registry to Predict Response to Immune Checkpoint Inhibitors for People with Stage I-IV Breast Cancer

Observational <span class="highlight">Basket</span> Study to Predict Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform (CYBRID-04)

Purpose: To create a registry to predict response to treatment with immune checkpoint inhibitors.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) triple negative (ER-, PR-, HER2-) breast cancer or breast cancer with TMB, MSI-H, or dMMR mutations who are planning to receive pembrolizumab (Keytruda®) or dostarlimab (Jemperli®). If you have stage I, stage II, or stage III breast cancer, you must have not yet received treatment. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will provide the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Biopsy sample</li> <li class="seamTextUnorderedListItem">Blood sample</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapy may help the body's immune system attack cancer and may reduce the ability of tumor cells to grow and spread.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) and dostarlimab (Jemperli®) are types of immunotherapy called PD-1 inhibitors, which are a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">MSI-H and dMMR mutations include MLH1, MSH2, MSH6, and PMS2.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li> <li class="seamTextUnorderedListItem">Targets or mutations: TMB, MSI-H, dMMR, MLH1, MSH2, MSH6, PMS2</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06349642' target='_blank'>ClinicalTrials.gov</a> </li></ul>
4

Registry to Predict Response to Immune Checkpoint Inhibitors for People with Stage I-IV Breast Cancer

Observational <span class="highlight">Basket</span> Study to Predict Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform (CYBRID-04)
Icon

Nearest Location:
2383 miles
Mayo Clinic in Florida
Jacksonville, FL

Icon

Visits:
1 visit

Icon

ClinicalTrials.gov: NCT06349642

Icon

Phase NA

5

Analyzing Tumor Mutations Before and After Treatment with Targeted Therapies

A <span class="highlight">Basket</span> Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy

Purpose: To compare genetic mutations seen in a tumor sample before and after treatment with a targeted therapy. The study will investigate how tumor mutations can be used to predict a cancer's response to treatment and how they change in response to targeted therapies.

Who is this for?: People who are receiving ongoing care at Memorial Sloan Kettering Cancer Center. View full eligibility criteria

What's involved?

<p class="seamTextPara"> All participants will be asked to provide: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">A tube of blood</li> <li class="seamTextUnorderedListItem">Cheek swab (also known as a buccal), or a saliva sample that contains normal genes for comparison</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Leftover tumor tissue from a previous surgery or biopsy will be used for genomic testing.</i></p>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Most genetic mutations found in cancer cells are not passed down from parents (inherited), but occur when the cells make mistakes when they divide.</li> <li class="seamTextUnorderedListItem">Most cancers have many mutations.</li> <li class="seamTextUnorderedListItem">Some of these mutations help drive the tumor's growth, while others are just bystanders.</li> <li class="seamTextUnorderedListItem">This type of study is called a <span class="highlight">basket</span> trial. <span class="highlight">Basket</span> trials enroll people based on the kind of mutations found in their tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT01775072' target='_blank'>ClinicalTrials.gov</a> </li></ul>
5

Analyzing Tumor Mutations Before and After Treatment with Targeted Therapies

A <span class="highlight">Basket</span> Study: Tumor Genomic Profiling in Patients Evaluated for Targeted Cancer Therapy
Icon

Nearest Location:
2494 miles
Lehigh Valley Health Network
Allentown, PA

Icon

Visits:
Number of visits unavailable

Icon

ClinicalTrials.gov: NCT01775072

Icon

Phase NA

HELP GUIDE
HELP GUIDE